RESEARCH

Every year Omikron Italia invests about 15% of its turnover in Research and Development on projects carried  out in collaboration with the most prestigious Italian and foreign Institutes.

The Main Fields of Research are the following:

1. Vasal Contractility and Permeability, for which there is a multi-year framework agreement with a US University Institute;

2. Preclinical development of a new flavonoid;

3. Hemorrhoidal disease:

  • a multicenter, prospective, randomized, controlled, triple-blind Clinical study, performed indipendently by the Italian Society of Colo-Rectal Surgery (SICCR) to evaluate the effectiveness of our mixture of flavonoids in the treatment of acute hemorrhoidal disease, has ended and was published in an International Journal;
  • the preclinical and clinical development of a new formulation for topical use in the treatment of hemorrhoids has just ended;

4. Retina:

  • an Experimental Trial on the treatment of Diabetic Retinopathy performed by an Italian University Institute has ended and was published in an International Journal;
  • an Experimental Trial performed by the National Health Institute (Istituto Superiore di Sanità) in vitro on retina cell cultures and in vivo with rats in order to assess the neuro-protective effect on structural and functional possible alteration on the retinal neuroglia component in the diabetic disease has ended and was published in an International Journal;
  • a Clinical Trial on the Treatment of Diabetic Retinopathy performed by an Italian Research Institute has ended and was published in an International Journal;
  • a Clinical Trial on corneal morphology and functionality performed by an Italian University Institute in patients with Diabetic Retinopaty has ended and is being published in an International Journal;

5. Glaucoma:

  • the first multicenter Experimentation with citicoline in oral solution, never carried out before on the progression of the campimetric damage in glaucomatous patients has been performed and was published in an International Journal;
  • the preclinical and clinical development of OMK1®, citicoline and hyaluronic acid in ophthalmic solution (Medical Device CE) and of OMK2®, citicoline, hyaluronic acid and vitamine B12 in ophthalmic solution (Medical Device CE) has been carried out in Italy;
  • a Clinical Trial performed by an Italian Research Institute with citicoline in ophthalmic solution in the treatment of glaucomatous patients has ended and was published in an International Journal;
  • a Clinical Trial performed by an Italian Institute on the treatment of patients with neurodegenerative diseases involving the optic nerve has ended and was published in an International Journal;
  • a multicenter Randomized Clinical Trial (RCT) with citicoline in ophthalmic solution in glaucomatous patients with progression damage has ended and is being published in an International Journal; this Trial has been performed by Italian University Institutes and provided morphological and functional evaluations;
  • an ocular kinetics study in human performed with citicoline in ophthalmic solution in patients undergoing vitrectomy has ended and was published in an International Journal;
  • the preclinical and clinical development of a new formulation for ophthalmic use in the treatment of glaucoma has just ended; first experimental and clinical studies with this new formulation have been already published in an International Journal;

 

PREMIO SOI a Omikron Italia
Go to top